Payment overview · 2025
General Payments
$1,019.67
55 reported records · 19 companies
Healthcare provider profile · identity verified
Kimberly Richardson, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PUNTA GORDA, FL · NPI 1952407553
Verified facts
What the public records show
CMS Open Payments records show Kimberly Richardson, ARNP received $1,019.67 in general payments during 2025 across 55 reported records.
Amgen Inc. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $196.01 | 19.2% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.32 | 13.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.66 | 10.7% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $73.11 | 7.2% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.09 | 6.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $65.11 | 6.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.57 | 5.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.10 | 4.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.57 | 3.8% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $34.03 | 3.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.34 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.92 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.20 | 2.8% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $20.78 | 2.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.35 | 1.9% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $17.31 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.06 | 1.7% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.14 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.00 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,019.67 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.66 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $102.02 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $93.99 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $93.99 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.01 | 5 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $73.11 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $69.09 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $65.11 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $56.19 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.87 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.31 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.10 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $34.03 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $33.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 51 |
| Lisinopril | Lisinopril | 160 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 131 | 39 |
| Losartan Potassium | Losartan Potassium | 96 | 28 |
| Gabapentin | Gabapentin | 93 | 27 |
| Omeprazole | Omeprazole | 76 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 24 |
| Simvastatin | Simvastatin | 73 | 24 |
| Trazodone Hcl | Trazodone Hcl | 72 | 20 |
| Montelukast Sodium | Montelukast Sodium | 69 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 31 |
| Meloxicam | Meloxicam | 60 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 18 |
| Eliquis | Apixaban | 55 | 16 |
| Furosemide | Furosemide | 54 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 17 |
| Azithromycin | Azithromycin | 43 | 34 |
| Potassium Chloride | Potassium Chloride | 42 | 18 |
| Alendronate Sodium | Alendronate Sodium | 41 | 16 |
| Allopurinol | Allopurinol | 40 | 13 |
| Famotidine | Famotidine | 37 | 14 |
| Prednisone | Prednisone | 37 | 23 |
| Metformin Hcl | Metformin Hcl | 36 | 15 |
| Ezetimibe | Ezetimibe | 34 | 14 |
| Ozempic | Semaglutide | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 11 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Mupirocin | Mupirocin | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,019.67 · 55 records | Amgen Inc. | ABRYSVO, AREXVY, CONTRAVE, Cologuard Collection Kit, ENTRESTO, EVENITY, EVKEEZA, GEMTESA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, Korlym, LEQVIO, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Senza, TERIPARATIDE, TRELEGY ELLIPTA, Tymlos, UBRELVY, VENASEAL, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error